Next generation mRNA vaccines, built for faster protection.
FUTR bio develops a proprietary mRNA vaccine platform to prevent and cure infectious diseases and cancer — engineered for single-dose efficacy and rapid, durable immune responses.
4
Active programs
2
Harvard & Yale advisors
5
PhD scientists
1
Proprietary mRNA platform
Cutting-edge science, engineered into better vaccines.
Our proprietary platform incorporates natural UTRs and molecular boosters that provide superior immune responses against infectious disease and cancer.
Faster protection
Fine-tuned control of the innate immune system accelerates the onset of protective immunity.
Single-dose design
Molecular boosters built into the mRNA reduce the need for repeat dosing regimens.
Platform, not a product
Natural UTRs and boosters are modular — applicable across infectious disease and oncology targets.
A platform, and a growing portfolio of programs.
Next Gen mRNA Vaccine Platform
COVID-19
H5N1
Fluvid (H5N1 + COVID)
Meet the team
Dr. Báfica has led scientific discoveries in the field of immunology and human pathogens, contributing to adjuvants and vaccine development. He developed solid scientific work at world-class institutions such as the National Institutes of Health, Rockefeller University and New York University, and was a nominated member of the Brazilian Academy of Sciences and the National Academy of Medicine. His contributions were recognized with awards including the Howard Hughes Medical Institute Early Career Investigator Competition and GRIP R01 NIH. Dr. Báfica is an associate professor at UFSC and a member of the Halo Team, a United Nations Verified Initiative helping end the pandemic.
Dr. Mansur's breakthrough research in molecular virology has contributed to unraveling innate recognition pathways of DNA and RNA viruses. Prior to forming his group in Brazil, he worked at world-class institutions such as Imperial College London and the University of Cambridge, securing funding for vaccine development and flavivirus biology from sources such as GSK and the Newton Fund / Royal Society. Dr. Mansur is a Brazilian leader in molecular virology and the development of CRISPR-based gene editing tools to understand microbial pathogenesis, and is an associate professor at UFSC.
Advised by world-leading immunologists
Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine. Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women's Hospital. Recipient of an NIH MERIT Award, the William Harvey Outstanding Scientist Medal, the AAAS Fellowship, the Society for Leukocyte Biology Bonazinga Award, the ACR Hench Award Lecture, the IUBMB Lecture Medal, the Ross Prize in Molecular Medicine, and the International Eicosanoid Research Foundation's Lifetime Achievement Award, among more than 50 keynote and plenary lectures delivered worldwide.
Professor of Immunobiology at Yale School of Medicine, member of Yale Cancer Center, and Howard Hughes Medical Institute Investigator. His research focuses on the innate immune system, inflammatory response, innate control of adaptive immunity, and host-pathogen interactions. Recipient of the William Coley Award, the Emil von Behring Award, the Blavatnik Award for Young Scientists, the Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research, and the Dickson Prize.
Let’s build the future of vaccines together.
Santo Antônio de Lisboa, Florianópolis – SC, Brazil